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Abstract 
Background:  Humoral immune responses against proteins of asexual blood‑stage malaria parasites have been asso‑
ciated with clinical immunity. However, variations in the antibody‑driven responses may be associated with a genetic 
component of the human host. The objective of the present study was to evaluate the influence of co‑stimulatory 
molecule gene polymorphisms of the immune system on the magnitude of the humoral immune response against a 
Plasmodium vivax vaccine candidate antigen.
Methods: Polymorphisms in the CD28, CTLA4, ICOS, CD40, CD86 and BLYS genes of 178 subjects infected with P. 
vivax in an endemic area of the Brazilian Amazon were genotyped by polymerase chain reaction‑restriction fragment 
length polymorphism (PCR‑RFLP). The levels of IgM, total IgG and IgG subclasses specific for ICB2‑5, i.e., the N‑terminal 
portion of P. vivax merozoite surface protein 1 (PvMSP‑1), were determined by enzyme‑linked immuno assay. The 
associations between the polymorphisms and the antibody response were assessed by means of logistic regression 
models.
Results: After correcting for multiple testing, the IgG1 levels were significantly higher in individuals recessive for 
the single nucleotide polymorphism rs3116496 in CD28 (p = 0.00004). Furthermore, the interaction between CD28 
rs35593994 and BLYS rs9514828 had an influence on the IgM levels (p = 0.0009).
Conclusions: The results of the present study support the hypothesis that polymorphisms in the genes of co‑
stimulatory components of the immune system can contribute to a natural antibody‑driven response against P. vivax 
antigens.
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Background
According to the World Health Organization, there were 
an estimated 200 million cases of malaria in 2014 and an 
estimated 584,000 resulting deaths worldwide [1]. Among 
the five species that can cause malaria in humans, Plas-
modium vivax is the most widely distributed, accounting 
for most of the cases of malaria in South and Southeast 
Asia, Latin America and Oceania; there are an estimated 
2.5 billion people living in areas at risk of transmission 
of the disease [1, 2]. Furthermore, although vivax malaria 
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has not been considered life-threatening for a long time, 
reports of severe cases associated with P. vivax have been 
increasingly numerous [3].
The blood stage of the Plasmodium lifecycle is respon-
sible for the pathology associated with malaria. In this 
stage, merozoites released from schizont-infected eryth-
rocytes invade non-infected erythrocytes, resulting in 
their destruction and the release of more merozoites into 
the bloodstream. During this brief extracellular period, 
these free merozoites are exposed to the host immune 
system, and proteins that are critical for parasite invasion 
are, therefore, important targets for the development of 
malaria vaccines. Merozoite surface proteins (MSPs) are 
among the most studied, especially MSP-1, which is nec-
essary for merozoite attachment to erythrocytes [4] and 
normal parasite development [5].
The most widely accepted structure of the P. vivax mer-
ozoite surface protein 1 (PvMSP-1) gene indicates that it 
consists of six polymorphic blocks (blocks 2, 4, 6, 8, 10 
and 12) flanked by seven conserved blocks (blocks 1, 3, 5, 
7, 9, 11 and 13) [6]. By analysing the primary structure of 
PvMSP-1, several seroepidemiological studies have been 
performed to evaluate its immunogenic potential [7–11]. 
Although the C-terminal portion of the protein (PvMSP-
119) is the most immunogenic [7, 9, 12], a number of 
studies showed high prevalence of IgG against N-termi-
nal PvMSP-1 in individuals exposed to P. vivax [9, 10, 
13, 14]. Furthermore, specific IgG3 antibodies against 
the N-terminal portion of PvMSP-1 have been associ-
ated with clinical protection in two riverine communities 
of the Brazilian Amazon [9, 11], similar to that observed 
in P. falciparum infection, where persistence of antibod-
ies IgG3 against N-terminal of MSP-1 was related with 
prolongation time without malaria [15]. In fact, antibod-
ies specific for the asexual blood stage are thought to be 
involved in clinical protection against malaria vivax. Lon-
gitudinal cohort studies have shown correlations between 
magnitude of antibody responses to P. vivax merozoite 
antigens and protection from malaria [11, 16–18]. Due to 
the inability in maintaining P. vivax in continuous in vitro 
culture, it is difficult to define the role of antibodies to 
this species, but few evidences support that it may be 
related to inhibition of merozoite invasion [19, 20]. Fur-
thermore, complement and FcR mediated mechanisms 
seem to be important in antibody-mediated protection 
[21].
The development of an adequate immune response 
depends on the fine regulation of lymphocyte activation. 
For this, in general, lymphocytes require two activation 
signals. The first signal is antigen-specific, whereas the 
second signal, called co-stimulation, is generated by the 
interaction between the surface molecules of T cells and 
those of antigen-presenting cells, including B cells. The 
interaction between CD28 and its ligands, CD80 and 
CD86, provides the strongest costimulatory signal for 
T-cell proliferation, whereas CTLA-4 is a negative regula-
tor that plays a key role in T cell homeostasis and in cen-
tral tolerance [22]. Another member of the CD28 family, 
Inducible co-stimulator (ICOS), is an important immune 
regulatory molecule that participates in T-cell activation 
and T-cell dependent B-cell responses [23, 24]. CD40 is 
presented on the surface of B-cells and the CD40-CD40L 
interaction is the major costimulatory signal for B cells to 
mount a humoral response [25]. B lymphocyte stimulator 
(BLYS) is produced mainly by innate immune cells and is 
needed to provide signals for B cell survival and prolifera-
tion [26]. Considering the importance of these molecules 
in development of immune response and because there 
are currently multiple lines of evidence showing that the 
genes involved in the immune response can influence 
antibody production during malaria infection [27–34], 
the authors hypothesised that polymorphisms in the 
genes of the co-stimulatory molecules CD28, CTLA-4, 
ICOS, CD86, CD40 and BLYS are involved in the magni-
tude of the naturally acquired antibody-driven response 
against N-terminal PvMSP-1 in individuals infected with 
P. vivax in the Brazilian Amazon.
Methods
Study area and subjects
The present study was conducted in the municipality of 
Goianésia do Pará, Pará state, Brazil, which is a constitu-
ent of the Brazilian Amazon region, where P. vivax is 
responsible for more than 80 % of all malaria cases [35]. 
Details of the study area have been described elsewhere 
[36]. Cross-sectional surveys conducted from February 
2011 to August 2012 were used to recruit 178 subjects 
(125 men and 53 women) presenting with classic symp-
toms of malaria, who sought treatment at the medical 
service of the municipality; the subjects had an average 
age of 29.8 years (varying from 14 to 68 years). Exclusion 
criteria included children under 10 years old, pregnancy, 
related individuals and anti-malarial treatment within 
the previous seven days. Diagnosis was performed by 
microscopy (thick film), and infection with P. vivax was 
subsequently confirmed by nested polymerase chain 
reaction (PCR) [37]. The geometric mean of parasiatemia 
was 718.4 parasites/mm3 (95  % CI 487.2–1059.2). All 
patients with microscopically confirmed infections were 
given standard treatment of 25 mg/kg of chloroquine in 
3 days plus 0.5 mg/kg of primaquine during seven days. 
All participants were submitted to a questionnaire to 
obtain epidemiological information. The length of resi-
dence in the municipality varied between one month and 
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37 years (median of 5 years), and 91.9 % of the individu-
als had previously contracted malaria. Samples from 40 
malaria-naive individuals living in a non-endemic area 
(São José do Rio Preto, Brazil), who had never been to 
areas of malaria transmission, were used as controls.
Peripheral venous blood (~10  mL) was collected in 
EDTA tubes, and plasma samples were obtained by cen-
trifugation and stored at −20  °C. The protocol of the 
present study was approved by the Research Ethics Com-
mittee of the Medical School of São José do Rio Preto 
(CEP/FAMERP no. 4599/2011) and by the health author-
ities of the municipality of Goianésia do Pará. All partici-
pants or their legal guardians signed an informed consent 
form.
Genotyping
DNA was extracted from peripheral blood samples with 
an Easy-DNA™ extraction kit (Invitrogen, California, 
USA). All single nucleotide polymorphisms (SNPs) were 
genotyped by PCR-restriction fragment length poly-
morphism (RFLP). The SNPs −372G > A and +17T > C 
in CD28 (rs35593994 and rs3116496, respectively), 
−318C  >  T and +49A  >  G in CTLA4 (rs5742909 and 
rs231775, respectively), +1564T > C in ICOS (rs4404254), 
+1057G  >  A in CD86 (rs1129055), −1C  >  T in CD40 
(rs1883832), and −871C  >  T in BLYS (rs9514828) were 
genotyped according to previously described protocols 
[36, 38, 39]. Primer sequences, restriction enzymes, and 
the restriction fragments obtained of each SNP are pre-
sented in Additional file 1. PCR for the identification of 
−1722T > C and −1577G > A in CTLA4 (rs733618 and 
rs11571316, respectively) was performed with a final 
sample volume of 25 µL containing 1X Buffer (20  mM 
Tris-HCl pH 8.4, 50 mM KCl), 1.5 mM MgCl2, 0.2 mM 
of each dNTP, 0.6 pmol of each primer, and 0.5 U Plati-
num Taq DNA Polymerase (Invitrogen, São Paulo, Bra-
zil). The primers 5′ CTTCATGCCGTTTCCAACTT 3′ 
and 5′ CCTTTTCTGACCTGCCTGTT 3′ were used 
for the −1722T  >  C genotyping, whereas 5′ CTTCAT 
GCCGTTTCCAACTT 3′ and 5′ ATCTCCTCCAGGAA 
GCCTCTT 3′ were used to identify −1577G > A. Ampli-
fications were performed under the following conditions: 
first step of 5 min at 94 °C, 35 cycles for 30 s at 94 °C, 30 s 
at 52 °C and 1 min at 72 °C, and a final step for 10 min at 
72 °C. The PCR products of −1722T > C and −1577G > A 
were digested with the enzymes BbvI and MboII (Fer-
mentas, Vilnius, Lithuania), respectively. Electrophoresis 
was performed in 2.5  % agarose and stained with Gel-
Red™ (Biotium, Hayward, USA) with the exception of the 
rs5742909 and rs1883832 SNPs, which were performed 
in 12.5 % polyacrylamide gel after staining with ethidium 
bromide, and visualized in a UV transilluminator.
Antigen and antibody determination
The glutathione-S-transferase (GST)-tagged recombinant 
ICB2-5 protein corresponds to the amino acids 170-675 
of the N-terminal portion of MSP-1 from the Belém strain 
of P. vivax. The ICB2-5-GST fusion protein was puri-
fied on a glutathione-Sepharose 4B column (Amersham 
Pharmacia), and the protein content was assessed with 
the Bio-Rad Protein Assay Kit I (Bio-Rad Laboratories, 
Inc.) [7]. The levels of IgM and IgG subclasses specific 
for ICB2-5 were measured as described previously with 
some modifications [7]. The plates were coated with GST-
tagged ICB2-5 and GST alone, and all tests were done in 
duplicate. Briefly, 50 µL of ICB2-5-GST or GST alone (as 
a control) was coated on ELISA plates at 4 µg/mL (Costar, 
Corning Inc., New York, USA) and incubated overnight 
at 4 °C. After washing and blocking the plates with 0.05 % 
bovine serum albumin-PBS, 50  µL of plasma diluted 
1/100 was added to the wells in duplicate and incubated 
for 1  h at 37  °C. Then, 50  µL of peroxidase-conjugated 
anti-human IgG or IgM antibodies (KPL, Maryland, USA) 
diluted 1/1000 were added to each well for the detection 
of total IgG or IgM, respectively. IgG subclasses were 
detected using mouse monoclonal antibodies specific 
for each isotype (Sigma, Missouri, USA), diluted accord-
ing to the tested subclass (1/3000 for IgG1 clone HP6001; 
and IgG3 clone HP6050, 1/2500 for IgG2 clone HP6014, 
and 1/5000 for IgG4 clone HP6025). The immobilized 
monoclonal antibodies were detected with peroxidase-
conjugated anti-mouse antibodies for 1 h at 37 °C (Sigma, 
Missouri, USA). Subsequently, the plates were washed 
and developed in the dark with 50  µL TMB substrate 
diluted 1/50 with 0.1 M phosphate-citrate buffer, pH 5.0, 
containing 0.03  % H2O2. The reaction was interrupted 
after 10 min by adding 50 µL of 2 N H2SO4 to each well 
and read at 450  nm. The determination of positivity for 
anti ICB2-5 was calculated as described previously, with 
some modifications [9]. Brief, firstly the average OD was 
calculated for each individual, and serum was considered 
positive if GST-tagged ICB2-5 OD was equal to or greater 
than cut off for this same protein, measured with sera of 
individuals who never had a past history of malaria. To 
confirm the positivity of a serum for anti ICB2-5, the aver-
age of GST-tagged ICB2-5 OD was calculated to exclude 
reactivity against GST. For each serum, the GST-cut 
off was calculated as average of GST OD plus twice the 
standard deviations (SD). The positivity for anti ICB2-5 
was determined when average of GST-tagged ICB2-5 OD 
was equal to or greater than its GST-cut off. The results 
are expressed as the reactivity index (RI), which was cal-
culated by dividing the OD of the sample by the cut-off 
value. Only the samples that were positive for total IgG 
(RI > 1) were tested for IgG subclasses.
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Statistical analysis
The associations between the SNP genotypes and the 
antibody response were analysed by means of a logistic 
regression model, controlling for potential confound-
ers, such as age and gender. Different genetic models 
(codominant, dominant, recessive and log-additive) were 
tested with the ‘SNPSassoc’ package [40] implemented 
for the R statistical software (version 3.1.1). A Bonfer-
roni correction was used to adjust for multiple testing, 
and the significance was set at p  <  0.005 (0.05/10). The 
sample size was calculated using GWAPower software 
[41]. The current sample size (n = 178) had 80 % power 
to detect a variant with about 6 % heritability. Since only 
90 samples were assessed for IgG subclasses, the power 
to detect the same heritability was about 42  %. Geno-
typic deviations from the Hardy–Weinberg equilibrium 
(HWE) were evaluated by using the exact test described 
by Wigginton et  al. [42]. Statistically significant differ-
ences between the means of continuous variables were 
assessed with one-way analysis of variance (ANOVA). 
Correlation coefficients of the antibody levels were esti-
mated with the Pearson correlation. Interactions between 
SNP pairs were also assessed with the ‘SNPassoc’ pack-
age, which determines the effects of interaction by means 
of log-likelihood ratio tests (LRTs).
Haplotype blocks were determined with Haploview 
4.2 using the solid spine of linkage disequilibrium (LD) 
method [43], and the degree of LD between SNPs was 
estimated with the D’ parameter. The R package ‘haplo.
stats’ [44] was used for association tests between hap-
lotypes and antibody levels by means of the ‘haplo.glm’ 
function, which performs a regression that estimates the 
effect of each haplotype compared to a reference haplo-
type by means of a general linear model.
Results
Serological data and single‑marker associations
Of the 178 subjects analysed, all infected with P. vivax, 
90 (50.6  %) exhibited IgG (RI  >  1), whereas 53 (29.8  %) 
exhibited IgM specific for ICB2-5. The antibody levels 
were higher for IgG1 (mean =  1.08) compared to those 
of the other subclasses (means of 0.91, 0.79 and 0.79 for 
IgG2, IgG3 and IgG4, respectively) (p < 0.001, ANOVA). 
The highest correlations between levels of IgG subclasses 
were found for IgG1 and IgG2 (r =  0.48) and IgG1 and 
IgG3 (r  =  0.43) (Additional file  2). The levels of ICB2-
5-specific antibodies were not influenced by previous 
exposure to malaria (age, length of residence in the stud-
ied area, and previous episodes of malaria) (Additional 
file 3), except for IgG2, which exhibited higher levels in 
individuals who reported to have had less than five previ-
ous episodes of malaria, compared to those who reported 
to have had more than five previous episodes [mean 
(confidence interval): 0.97 (0.84–1.10) vs. 0.88 (0.76–
0.99), p = 0.01, ANOVA].
 The allelic and genotype frequencies of all the analysed 
SNPs are listed in Table 1 and Additional file 4. The allele 
frequencies of these SNPs were previously presented in 
a larger set of samples (with exception of SNPs rs733618 
and rs11571316) [45]. The success rate of SNP genotyp-
ing was 100  % for eight of the studied SNPs, whereas 
rs733618 and rs11571316 were successfully genotyped in 
88.2 and 82 % of the samples, respectively, and no devia-
tion from HWE was observed (all p value >0.1). A sum-
mary of the statistics for all the evaluated SNPs is listed 
in Table 1 and Additional file 4. There is not significant 
association between the polymorphisms and parasi-
taemia (all p value  >0.07, Kruskal–Wallis test, data not 
show). Three SNPs were significantly associated with 
the humoral immune response against P. vivax ICB2-
5. IgM levels were associated with rs35593994 in CD28; 
individuals with the GG genotype had lower antibody 
levels (mean 0.67 vs. 0.88, p =  0.03). Based on a reces-
sive model, individuals with a CC genotype for rs3116496 
in CD28 exhibited higher IgG1 levels with respect to 
the other genotypes (mean 3.13 vs. 1.04, p  =  0.00004). 
Individuals with a TC genotype for rs733618 in CTLA4 
exhibited higher IgG2 levels with respect to homozy-
gous individuals (mean 1.18 vs. 0.87, p = 0.04). However, 
after correction for multiple testing, only association that 
remained significant was the one with CD28 (re3116496).
Linkage disequilibrium analysis and haplotype association
Linkage disequilibrium analysis was performed for all 
possible pairwise combinations of seven SNPs that were 
analysed across 255 kb in the 2q33 chromosomal region, 
which encompasses CD28, CTLA4 and ICOS. Two hap-
lotype blocks were defined using the criterion described 
by Barret et al. [43] (Fig. 1). Three haplotypes of block 1, 
which contains rs35593994 and rs3116496 in CD28, were 
built, with frequencies varying between 18.5 and 52.2 %, 
and for block 2, which contains rs733618, rs11571316 
and rs5742909 in the promoter region of CTLA4, four 
haplotypes were built, with frequencies varying between 
6.3 and 51.8 %. The effects of each haplotype on the anti-
body levels were estimated and are shown in Table 2. The 
AT haplotype in block 1 was significantly associated with 
a 20 % increase in IgM levels (p = 0.027) with respect to 
the reference haplotype (specifically, the most frequent 
haplotype, i.e., CT). However, no association remained 
significant after correction for multiple testing.
Interaction analysis
Using the R project package ‘SNPassoc’ [40], the study 
explored all pairwise SNP−SNP interactions under the 
codominant model. These interactions are represented 
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graphically in Fig.  2, in which the upper part contains 
the p values for the interaction LRT. Although several 
significant associations involving rs3116496 in CD28 
and other SNPs (rs1129055, rs5742909 and rs231775) 
with IgG1 levels were observed, the level of significance 
was below that found for rs3116496 individually (all 
p values  >0.0001). However, the interaction involving 
rs35593994 in CD28 with rs9514828 in BLYS was associ-
ated with the IgM levels (p = 0.0009). A regression anal-
ysis was performed to confirm this interaction, and the 
results of significant associations involving the above two 
SNPs are listed in Table 3.
Discussion
The main strategies used for malaria control are based 
on prompt diagnosis and treatment and on vector con-
trol. However, new resistant parasite strains arise as new 
drugs are applied, and vector control is also encountering 
great challenges due to the growing resistance to insec-
ticides, thus justifying research on the development of a 
vaccine that is effective against malaria. Characterisation 
of the naturally acquired immune response in different 
populations is a useful tool for the identification of mol-
ecules that can be targeted by anti-malarial vaccines.
The present study was to evaluate the naturally 
acquired immune response against the N-terminal por-
tion of PvMSP-1. Although the C-terminal portion 
(MSP-119) is considered to be the most immunogenic 
region of the protein [7, 9, 12], there is evidence sug-
gesting that antibodies targeting the N-terminal portion 
Table 1 Levels of Plasmodium vivax ICB2-5-specific IgM, IgG and IgG subclasses with respect to the analysed genotypes 
from individuals infected with P. vivax
a Number of individuals evaluated for ICB2-5-specific IgM and total IgG (n = 178)
b Number of individuals evaluated for ICB2-5-specific IgG subclasses (n = 90)
c Significant according to the dominant model (p = 0.033)
d Significant according to the recessive model (p = 0.00004)
e Significant according to the overdominant model (p = 0.042)




IgG (RI) IgG1 (RI) IgG2 (RI) IgG3 (RI) IgG4 (RI) IgM (RI)
rs35593994 CD28 GG/GA/AA 86/80/12 42/39/8 1.02/1.03/1.11 1.11/1.10/0.89 0.92/0.93/0.80 0.76/0.86/0.64 0.77/0.83/0.74 0.66/0.86/1.13c
rs3116496 CD28 TT/TC/CC 118/54/6 60/27/2 1.04/1.02/0.91 1.06/0.98/3.13d 0.91/0.92/0.95 0.82/0.72/0.75 0.82/0.75/0.67 0.83/0.70/0.65
rs733618 CTLA4 TT/TC/CC 135/20/2 72/7/1 1.06/0.89/1.05 1.11/0.97/0.81 0.87/1.18/0.64e 0.80/0.66/0.57 0.80/0.68/0.62 0.82/0.72/1.25
rs11571316 CTLA4 GG/GA/AA 59/75/12 29/39/4 1.04/1.03/0.97 1.17/1.10/0.84 0.96/0.95/0.68 0.74/0.86/0.56 0.73/0.82/0.66 0.81/0.75/0.79
rs5742909 CTLA4 CC/CT/TT 151/27/0 75/14/0 1.15/1.01/– 1.04/1.29/– 0.91/0.93/– 0.80/0.76/– 0.80/0.78/– 0.79/0.78/–
rs231775 CTLA4 AA/AG/GG 75/84/19 40/41/8 1.07/1.00/1.01 0.96/1.22/0.98 0.87/0.98/0.82 0.78/0.82/0.70 0.79/0.79/0.81 0.79/0.75/0.89
rs4675378 ICOS TT/TC/CC 77/73/27 35/38/16 1.00/1.05/1.09 1.08/1.12/0.99 0.86/0.94/0.96 0.73/0.90/0.67 0.80/0.78/0.80 0.80/0.73/0.85
rs1129055 CD86 GG/GA/AA 110/60/8 53/31/5 1.00/1.08/1.15 1.08/1.09/1.06 0.93/0.90/0.93 0.78/0.82/0.70 0.82/0.76/0.70 0.81/0.73/0.90
rs1883832 CD40 CC/CT/TT 135/37/6 65/20/4 1.01/1.06/1.25 1.11/1.03/0.86 0.92/0.95/0.68 0.81/0.77/0.65 0.81/0.75/0.79 0.80/0.69/1.13
rs9514828 BLYS CC/CT/TT 103/62/13 48/35/6 0.99/1.07/1.15 0.99/1.23/0.98 0.91/0.94/0.83 0.82/0.69/1.11 0.76/0.81/0.92 0.73/0.83/0.95
Fig. 1 Linkage disequilibrium of investigated polymorphisms in 
region 2q33, which comprises genes CD28, CTLA4 and ICOS. The num-
bers within the squares represent the D’ value, expressed as per cent. 
Empty squares represent a D’ value of 1, which indicates complete 
linkage disequilibrium. Darker-shaded squares represent pairs with an 
LOD score = 2, light grey squares represent D’ = 1 and LOD < 2, and 
white squares represent LOD < 2 and D’ < 1. Two blocks were identified 
by means of the solid spine of linkage disequilibrium method [37]. 
Linkage Disequilibrium map was generated by Haploview 4.2
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of MSP-1 provide clinical protection during infections 
with both P. falciparum [46, 47] and P. vivax [9, 11]. The 
results of the IgG-mediated humoral immune response 
showed that ICB2-5 was detected by just over half of the 
studied individuals (50.6 %). This prevalence of respond-
ers is similar to that found in individuals infected with P. 
vivax in other places of the Brazilian Amazon [8, 11]. A 
small percentage (~10 %) of the individuals who reported 
having had several previous episodes of malaria exhibited 
high IgM levels, but no IgG was evidenced, suggesting 
that class switching from IgM to IgG may be impaired. 
This observation has been reported in previous studies 
[8, 48], and Soares et al. [8] suggested that this impaired 
switch from IgM to IgG may be related to deficient 
CD40/CD40-L interactions. Thus, the authors evaluated 
Fig. 2 Interaction between SNPs in the codominant model. The diagonal contains the p values of the likelihood ratio test (LRT) for the effect of 
each SNP individually. The upper triangle in the matrix contains the p values for the interaction log‑LRT. The lower triangle contains the p values from 
LRT comparing the two‑SNP additive likelihood to the best finding of the single‑SNP model [35]
Table 3 Significant interactions between  the SNPs 
rs35593994 and  rs9514828 and  the levels of  IgM specific 
for ICB2-5
a Antibody levels are expressed as the mean of the reactivity index (RI)
b Difference of the RI mean
c Based on a logistic regression model using individuals exhibiting wild type 







∆b 95 % CI pc
GG CC 0.503 Reference
GG CT 1.025 0.523 (0.195–
0.850)
0.002
GA CC 0.916 0.413 (0.126–
0.702)
0.005
GA TT 1.441 0.939 (0.395–
1.483)
0.0009
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whether co-stimulatory molecule gene polymorphisms 
are involved in the delayed class switch from IgM to IgG. 
However, no association was observed.
Regarding IgG subclasses, higher levels of IgG1 were 
found compared to the other IgG subclasses, which is 
in contrast to previous studies showing a predominance 
of IgG3 specific for ICB2-5 [8, 9, 11]. Although there is 
still no consensus regarding the role of antibody sub-
classes in clinical protection, it has been suggested that 
only the cytophilic subclasses, i.e., IgG1 and IgG3, are 
protective [49, 50]. Two longitudinal studies performed 
in the Brazilian Amazon, specifically, one in Portu-
chuello, near Porto Velho, and the other in a commu-
nity of Rio Pardo, Amazonas state, have observed that 
ICB2-5-specific antibodies were associated with clini-
cal protection against malaria caused by P. vivax and 
that IgG3 was detected in all asymptomatic individuals, 
whereas most symptomatic patients exhibited no IgG3 
[9, 11]. If the above results were to be extrapolated to 
Goianésia do Pará, the site of this study, the fact that a 
passive collection was performed on patients exhibit-
ing symptoms could explain the low IgG3 levels found. 
Furthermore, some studies have also shown that IgG2 
may be associated with protection. Deloron et al. [51] 
found an association between high IgG2 levels and low 
risk of acquiring an infection by P. falciparum. Although 
the design of the present study does not allow for the 
association of the prevalence and levels of clinically 
protective antibodies, higher IgG2 levels were observed 
in subjects who reported having had fewer cases of 
malaria.
The development of an immune response against Plas-
modium species is a complex process, and one of the 
main issues is understanding why individuals differ in 
their immune responses against the parasite. Thus, the 
objective of the present study was to investigate the influ-
ence of co-stimulatory molecule gene polymorphisms on 
the production of antibodies specific for an important 
P. vivax vaccine candidate antigen. The most important 
result was that CD28 rs3116496 was associated with lev-
els of IgG1 specific for ICB2-5. In addition to the impor-
tant role of CD28 in T cell activation, the binding of this 
receptor to its ligands CD80 and CD86 on the surface of 
B cells provides bidirectional signals that appear to be 
important for IgG production by B cells [52]. Thus, CD28 
may be involved in the immune response against malaria. 
In fact, CD28 knockout mice infected with Plasmodium 
chabaudi were unable to resolve the infection, main-
taining low levels of parasitaemia for weeks after infec-
tion [53, 54]. Furthermore, treatment of wild type mice 
with monoclonal anti-CD86 antibodies abolished IL-4 
production and was significantly associated with reduced 
levels of P. chabaudi-specific IgG1 [55].
In the present study, individuals exhibiting the T allele 
for rs3116496 in CD28 were found to be associated with 
reduced IgG1 levels. Although the biological functions 
of this SNP, which is located in the third intron of the 
gene, are still unknown, it is located near a splice site, 
at which point mutations can induce abnormal splicing, 
thus affecting protein expression [56]. The relationship 
between rs3116496 in CD28 and susceptibility to several 
diseases has already been evaluated, and significant asso-
ciations have been found in type 1 diabetes [57], cervi-
cal [58] and breast cancer [59], and rheumatoid arthritis 
[60]. However, the role of this polymorphism in malaria 
has not yet been assessed, and even if the presence of the 
T allele, which is associated with lower levels of ICB2-
5-specific IgG1, were implicated in higher susceptibil-
ity to vivax malaria, further elucidation would still be 
necessary.
Although it seems likely that immunity against malaria 
is affected by several genes, the influence of combined 
polymorphisms is rarely ever investigated. The present 
study performed analyses of interactions between the 
SNP pairs and found that CD28 rs35593994 and BLYS 
rs9514828 together were associated with levels of IgM 
specific for ICB2-5, especially in individuals with GA 
and TT genotypes, respectively. Specifically, they were 
associated with a ~180  % increase in IgM levels com-
pared to that of wild type genotype individuals. Although 
the biological mechanisms underlying this interaction 
are still unknown, CD28 and BLyS may be involved in 
the production of memory B cells and antibody isotype 
class switching [61, 62]. Both polymorphisms, i.e., CD28 
rs35593994 and BLYS rs9514828, are located in the 5′ 
regulatory region of the gene; thus, differential expres-
sion of these genes may change the regulation of the B 
cells involved in the production of ICB2-5-specific anti-
bodies. Liu et al. [63] have shown that despite the genera-
tion of memory B cells as a response to vaccination with 
MSP-119, the function of these cells was nullified due to 
a lack of BLyS expression in dendritic cells from mice 
infected with P. yoelii.
Although it was observed the influence of these two 
SNPs in the antibody response to ICB2-5, most of the 
evaluated polymorphisms did not show any significant 
differences. In fact, variations in the immune response to 
malaria can be attributed to several factors, including the 
environment, previous exposure to malaria and immuno-
genicity of antigen. Thus, as a complex trait, it is likely that 
many polymorphisms have small effect in malaria immune 
response, but large sample size is required to detect it.
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Conclusions
In summary, several genes involved in the control of 
the immune response were investigated, entailing the 
production of antibodies against a P. vivax vaccine can-
didate antigen. Despite the growing number of stud-
ies evaluating human genetic factors that control the 
immune response to malaria [27–34, 64], it is likely 
that many genes responsible for the wide inter-individ-
ual variation observed in the immune response against 
malaria remain unknown; studies similar to the present 
work may help identify subjects who are more prone to 
respond to a specific vaccine [29]. Although the statis-
tical evidence supporting the described associations is 
limited by the relatively small sample size and, although 
it is impossible to tell whether the SNPs studied here 
are truly causal or are in LD with the causal variants, 
the results suggest that genetic variations in CD28 and 
interactions between polymorphisms in BLYS and CD28 
may be involved in the control of the immune response 
against vivax malaria.
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